Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, Baath J, Buys YM (2013) Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol 58:291–310. https://doi.org/10.1016/j.survophthal.2012.08.003

Article  PubMed  Google Scholar 

Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914. https://doi.org/10.1016/j.ophtha.2014.04.024

Article  PubMed  Google Scholar 

London NJ, Chiang A, Haller JA (2011) The dexamethasone drug delivery system: indications and evidence. Adv Ther 28:351–366. https://doi.org/10.1007/s12325-011-0019-z

Article  CAS  PubMed  Google Scholar 

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134-1146.e3. https://doi.org/10.1016/j.ophtha.2010.03.032

Article  PubMed  Google Scholar 

Unsal E, Eltutar K, Sultan P, Erkul SO, Osmanbasoglu OA (2017) Efficacy and safety of intravitreal dexamethasone implants for treatment of refractory diabetic macular edema. Korean J Ophthalmol 31:115–122. https://doi.org/10.3341/kjo.2017.31.2.115

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allergan Ozurdex SA (n.d) (Dexamethasone Intravitreal Implant) for Intravitreal Injection - Full Prescribing Information. p. Page 5.

Maturi RK, Pollack A, Uy HS, Varano M, Gomes AM, Li XY, Cui H, Lou J, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2016) Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD Study. Retina 36:1143–1152. https://doi.org/10.1097/iae.0000000000001004

Article  CAS  PubMed  Google Scholar 

Chin EK, Almeida DRP, Velez G, Xu K, Peraire M, Corbella M, Elshatory YM, Kwon YH, Gehrs KM, Boldt HC, Sohn EH, Russell SR, Folk JC, Mahajan VB (2017) ocular hypertension after intravitreal dexamethasonE (Ozurdex) sustained-release implant. Retina 37:1345–1351. https://doi.org/10.1097/iae.0000000000001364

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mazzarella S, Mateo C, Freixes S, Burés-Jelstrup A, Rios J, Navarro R, García-Arumí J, Corcóstegui B, Arrondo E (2015) Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema. Ophthalmic Res 54:143–149. https://doi.org/10.1159/000438759

Article  CAS  PubMed  Google Scholar 

Johnson DH, Bradley JM, Acott TS (1990) The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Invest Ophthalmol Vis Sci 31:2568–2571

CAS  PubMed  Google Scholar 

Steely HT, Browder SL, Julian MB, Miggans ST, Wilson KL, Clark AF (1992) The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 33:2242–2250

CAS  PubMed  Google Scholar 

De Gregorio A, Pedrotti E, Stevan G, Bertoncello A, Morselli S (2018) XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice. Clin Ophthalmol 12:773–782. https://doi.org/10.2147/opth.S146919

Article  PubMed  PubMed Central  Google Scholar 

Malclès A, Dot C, Voirin N, Vié AL, Agard É, Bellocq D, Denis P, Kodjikian L (2017) Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina 37:1352–1359. https://doi.org/10.1097/iae.0000000000001369

Article  PubMed  Google Scholar 

Nguyen T, Kim H, Mielke C, Momont AC, Brandt JD, Liu Y (2020) Combined dexamethasone intravitreal implant and glaucoma drainage device placement for uveitic glaucoma. J Glaucoma 29:252–257. https://doi.org/10.1097/ijg.0000000000001454

Article  PubMed  PubMed Central  Google Scholar 

Clark AF, Wilson K, de Kater AW, Allingham RR, McCartney MD (1995) Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci 36:478–489

CAS  PubMed  Google Scholar 

Clark AF, Wordinger RJ (2009) The role of steroids in outflow resistance. Exp Eye Res 88:752–759. https://doi.org/10.1016/j.exer.2008.10.004

Article  CAS  PubMed  Google Scholar 

Pérez-Sarriegui A, Casas-Llera P, Díez-Álvarez L, Contreras I, Moreno-López M, Figueroa MS, González-Martín-Moro J, Muñoz-Negrete FJ, Rebolleda G (2018) Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant. Arch Soc Esp Oftalmol (Engl Ed) 93:580–585. https://doi.org/10.1016/j.oftal.2018.06.011

Article  PubMed  Google Scholar 

Vié AL, Kodjikian L, Malclès A, Agard E, Voirin N, El Chehab H, Nguyen AM, Dot C (2017) Tolerance of intravitreal dexamethasone implants in patients with ocular hypertension or open-angle glaucoma. Retina 37:173–178. https://doi.org/10.1097/iae.0000000000001114

Article  PubMed  Google Scholar